Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer

Far Eastern Memorial Hospital

Status: Not yet enrolling

Conditions: Intravenous Chemotherapy Versus Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer

Treatments: Drug: Chemotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT06535334

113130-E

Details and patient eligibility

About

This study aims to compare intravenous chemotherapy versus intraperitoneal chemotherapy in patients with recurrent ovarian cancer.

Enrollment: 80 estimated patients

Sex: Female

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• women who had recurrent ovarian cancer and was treated with either intravenous or intraperitoneal platinum based chemotherapy

Exclusion criteria

• women who did not complete the designated treatment course (exception to those who had to quit due to progressive disease or death of any cause)

Trial design

80 participants in 2 patient groups

intravenous chemotherapy

Description:

triweekly chemotherapy with carboplatin AUC=5\~6 + liposomal-doxorubicin 30\~40mg/m2 or paclitaxel 175mg/m2 0r docetaxel 60\~75mg/m2

Treatment:

Drug: Chemotherapy

intraperitoneal chemotherapy

Description:

Day 1 IV Paclitaxel 135 mg/m2 + IP Cisplatin 75-100 mg/m2 or IP carboplatin (AUC = 6) Day 8 IP Paclitaxel 60 mg/m2 Every 21 days \* 6 cycles OR Day 1 IP Carboplatin AUC=5 or IP Cisplatin 50-75mg/m2 Day 2 IV Liposomal doxorubicin 15 mg/m2 + IP Liposomal doxorubicin 15 mg/m2 Every 28 days \* 6 cycles

Treatment:

Drug: Chemotherapy